PSLNR
PSLNR may be a candidate diagnosis and therapeutic target for PCa.[1]
Contents
Annotated Information
Name
Approved symbol:PSLNR
Approved name:prostate enriched lncRNA
HGNC ID:54405
Alias symbol:LA16c-83F12.6
RefSeq ID:NR_132385
Characteristics
Please input information here.[1]
Function
PSLNR inhibited PCa progression via the p53-dependent pathway.[1]
Regulation
PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner.[1]
Expression
PSLNR exhibited a highly prostate‐specific expression pattern, with little to no expression in other human tissue types by using the GTEx cohort.[1]
PSLNR was specifically expressed in the prostate.[1]
Diseases
Prostate cancer (PCa)[1]
Labs working on this lncRNA
- State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, School of Life Science, Fudan University, Shanghai, PR China.[1]
- Department of Urology, Shanghai Four People's Hospital Affiliated to Tongji University School of Medicine, Shanghai, PR China.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Wang D, Wan X, Zhang Y, Kong Z, Lu Y, Sun X, Huang Y, Ji C, Li D, Luo J, Gu W, Wang C, Li Y, Xu Y. A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway. Prostate. 2019 Sep;79(12):1362-1377. doi: 10.1002/pros.23840. Epub 2019 Jul 3.
